RT Journal Article
SR Electronic
T1 High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 825
OP 830
DO 10.3899/jrheum.121358
VO 40
IS 6
A1 Anna Jamnitski
A1 Johannes H. Levels
A1 Inge A. van den Oever
A1 Michael T. Nurmohamed
YR 2013
UL http://www.jrheum.org/content/40/6/825.abstract
AB Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response. Methods. A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Results. In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months’ therapy. There were no significant differences in HDL profiling in EULAR nonresponders. Conclusion. Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition.